IGI Logo

Zydus Lifesciences is currently trading at Rs. 922.90, up by 21.30 points or 2.36% from its previous closing of Rs. 901.60 on the BSE.

The scrip opened at Rs. 903.60 and has touched a high and low of Rs. 922.90 and Rs. 894.80 respectively. So far 15418 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 863.80 on 16-Feb-2024.

Last one week high and low of the scrip stood at Rs. 998.95 and Rs. 894.80 respectively. The current market cap of the company is Rs. 92382.34 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.18% and 6.84% respectively.

Zydus Lifesciences’ wholly owned subsidiary, Zydus Lifesciences Global FZE has inked an exclusive licensing, supply and commercialization agreement with Zhuhai Beihai Biotech Co. for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market.

The partnership will provide impetus to company’s strategic focus on high unmet need therapy area. BEIZRAY is indicated for the treatment of Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma, and Head and Neck Cancer. Under the agreement, Beihai Biotech will be responsible for the manufacturing and supply of the product, while Zydus will be responsible for commercialization of the product in the US. Beihai Biotech shall receive upfront payments, sales targets-based milestone payments and a share of BEIZRAY’s net profits earned in the US as per the terms of the agreement.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.